Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Other Non-Current Assets (2017 - 2026)

DiaMedica Therapeutics filings provide 6 years of Other Non-Current Assets readings, the most recent being $400000.0 for Q1 2026.

  • Quarterly Other Non-Current Assets changed N/A to $400000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $400000.0 through Mar 2026, changed N/A year-over-year, with the annual reading at $400000.0 for FY2025, 69.42% down from the prior year.
  • Other Non-Current Assets hit $400000.0 in Q1 2026 for DiaMedica Therapeutics, roughly flat from $400000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.3 million in Q1 2024 and bottomed at $400000.0 in Q4 2025.
  • Average Other Non-Current Assets over 3 years is $1.0 million, with a median of $1.3 million recorded in 2024.
  • Peak annual rise in Other Non-Current Assets hit 69.42% in 2025, while the deepest fall reached 69.42% in 2025.
  • DiaMedica Therapeutics' Other Non-Current Assets stood at $1.3 million in 2024, then plummeted by 69.42% to $400000.0 in 2025, then changed by 0.0% to $400000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Other Non-Current Assets are $400000.0 (Q1 2026), $400000.0 (Q4 2025), and $1.3 million (Q4 2024).